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Background: We implemented a selective medium for improved detection of Stenotrophomonas maltophilia in sputum samples from CF patients.
We also performed antimicrobial susceptibility testing with eight antibiotics.
Methods: A total of 623 consecutive sputum samples from 165 CF patients in a German CF center were cultured onto conventional media and
onto Steno medium agar (SMA). All isolates confirmed as S. maltophilia by biochemical and molecular methods were subjected to antimicrobial
susceptibility testing. The following agents were tested by Etest: ceftazidime, levofloxacin, moxifloxacin, tigecycline, trimethoprim–
sulfamethoxazole, fosfomycin, colistin, and ticarcillin–clavulanate acid.
Results: Conventional media supported the growth of S. maltophilia in 7.1% of samples, whereas SMA supported its growth in 11.6%, increasing
the detection rate to 64%. Trimethoprim–sulfamethoxazole and tigecycline exhibited the highest in vitro activity, whereas ceftazidime, colistin,
and ticarcillin–clavulanate acid exhibited higher resistance rates.
Conclusions: SMA is a promising medium allowing improved isolation of S. maltophilia from sputum samples from CF patients. Trimethoprim–
sulfamethoxazole and tigecycline demonstrated excellent inhibitory effects against S. maltophilia, which may suggest a potential clinical effect.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; S. maltophilia; Selective agar; Susceptibility testing1. Introduction
Apparently, anti-pseudomonal therapy has caused a selective
pressure on the CF bacterial polymicrobial community and has led
to the emergence of new pathogens in the CF lung [1]. Data from
several CF centers worldwide indicate that the prevalence of
Stenotrophomonas maltophilia has increased in recent years [2].
S.maltophilia is an opportunistic, nonfermentative, gram-negative
rod, first isolated in 1943 and named Bacterium bookeri [3].
However, the first report of S. maltophilia in a CF patient did not
appear until 1979 [4]. S. maltophilia is considered a ubiquitous⁎ Corresponding author at: Institute of Medical Microbiology, University
Hospital Essen, Hufelandstrasse 55, D-45122 Essen, Germany. Tel.: +49 201
72385771; fax: +49 201 7235602.
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1569-1993/$ - see front matter © 2011 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2011.06.010organism that can also be isolated from various nosocomial
sources [5,6].
Even though S. maltophilia commonly colonizes the
respiratory tract of CF patients, its pathogenic importance in
the progression of CF lung disease has not yet been completely
clarified. Nevertheless, in a very recently study Waters et al. [7]
showed that chronic S. maltophilia infection is an independent
risk factor for pulmonary exacerbation. Therefore, isolation of
this microorganism from CF sputum samples may become a
cause of concern for the CF community.
Sputum culture is still the gold standard for the detection of
bacteria and fungi in the respiratory tract of CF patients.
Because microorganisms such as P. aeruginosa and Aspergillus
fumigatus can easily overgrow on solid media, isolation and
identification of other potentially pathogenic microorganisms
can often be challenging to microbiology laboratories [8]. Usingd by Elsevier B.V. All rights reserved.
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pathogens such as P. aeruginosa, Burkholderia cepacia, or
Scedosporium spp. has been shown to increase the isolation
rates [8–10]. S. maltophilia exhibits an inherently resistant
profile against a plethora of antibiotic agents. For this reason,
specific isolation of S. maltophilia through a selective agar
including broad-spectrum anti-infective agents that suppress
bacterial and fungal co-flora can be a powerful diagnostic tool.
S. maltophilia exhibits substantial resistance to broad-
spectrum antibiotics, including beta-lactams; therefore, treat-
ment options are limited. Very little information exists about the
in vitro activity of antimicrobial agents against S. maltophilia,
especially for CF patients [11]. Because strategies for the
development of new drugs are lacking, the effectiveness of
available antimicrobial agents against S. maltophilia must be
demonstrated. Additionally, no studies have determined
the activity of fosfomycin, tigecycline or colistin against
S. maltophilia in CF patients, even though colistin inhalation
therapy is commonly used to treat CF patients infected with
multidrug-resistant bacteria.
In this study we report the development and utility of a
selective medium for improved isolation of S. maltophilia and
compare it to conventional media. We also report the activity of
eight antimicrobial agents against this organism.2. Material and methods
2.1. Study design and setting
The University Hospital Essen is a German tertiary care
teaching hospital with 1300 beds; it treats approximately 50,000
inpatients per year. The Department of Pediatric Pulmonology
of the Children's Hospital and the West German Lung Centre of
the University Hospital Essen care for approximately 250 CF
patients.
The Institute of Medical Microbiology of the University
Hospital Essen is responsible for processing all samples from
the CF patient collective. In this observational prospective
cohort study, sputum samples were collected from consecutive
CF patients admitted between January 2009 and February 2011.2.2. Culture on conventional media
A total of 623 sputum samples from 165 CF patients were
investigated for growth of S. maltophilia by inoculating 10 μL
of sputum onto routinely implemented media. In some cases,
when sputum exhibited a very mucoid aspect, an equal volume
of SPUTASOL (LIQUID) (Oxoid, Wesel, Germany) was
added, and this solution was vigorously homogenized on a
vortex mixer at room temperature. The solid media used were
Columbia agar with sheep blood, chocolate agar, McConkey
agar, Candida chrom agar (Brilliance), and malt agar (all from
Oxoid, Wesel, Germany). The incubation period for most media
was 48 h at 35 °C, except for malt agar, which was incubated
for an additional 8 days at room temperature.2.3. Culture on selective media
Steno medium agar (SMA) was formulated as previously
described [12] with slight modifications. SMA was prepared by
adding 40 g of blood agar base (Fa. Oxoid, CM 55) to 1 L of
distilledwater. This solution was autoclaved for 15 min at 121 °C,
after which the medium was cooled to 50 °C to 60 °C in a water
bath and the pHwas adjusted to 7.0 to 7.2. Fresh-filtered sterilized
solutions of amphotericin B (SIGMA-ALDRICH, St. Louis, MO,
USA), imipenem (ZIENAM,Merck Sharp&Dohme,City, India),
and vancomycin (ratiopharm, Ulm, Germany) were then added to
yield final concentrations of 2.5 mg, 32 mg, and 10 mg,
respectively. The medium was poured into petri dishes (diameter,
90 mm) and stored for as long as 3 weeks at 4 °C. Validation of
the medium was performed by culturing S. maltophilia (ATCC
13637) and an imipenem-susceptible Klebsiella pneumoniae
reference strain (ATCC10031) for as long as 25 days. This quality
control demonstrated that SMA remains stable for no more than
21 days because imipenem activity is gradually reduced over time.
An aliquot from each fresh sputum sample (not older than
3 days and stored at 4 °C) was plated onto SMA and incubated
aerobically at 35 °C for up to 48 h.
2.4. Identification of S. maltophilia
S. maltophilia isolates were identified by conventional
standardized laboratory methods (growth conditions, morpho-
logical criteria, pigment production, etc.) and by negative or
slowly positive results on the oxidase test. Species identification
was confirmed with the MicroScan® Walkaway system
(Siemens, Erlangen, Germany). If identification was not clear,
API 20 NE strips (bioMérieux, Basingstoke, UK) were used
(Fig. 1). S. maltophilia reference strain ATCC 13637 was used
as a quality control.
DNA sequencing was used to confirm the identification of
S. maltophilia clinical isolates. For amplification of the 16S
region we used the following pair of primers: DG 74: 5′-AGG
AGG TGA TCC AAC GCG A-3′; RW01: 5′-AAC TGG AGG
AAG GTG GGG AT-3′, which generated amplicons of 300 to
350 bp. PCR amplification was performed as previously
described by Greisen et al. [13]. The sequences obtained were
submitted to the databank of the National Center for Biotechnol-
ogy Information (NCBI, Bethesda, MD, USA) through the
BLASTn platform, with a cut-off of 98% for species identifica-
tion. Isolates were frozen at −80 °C until MIC testing was
performed.
2.5. Determination of minimum inhibitory concentration (MIC)
A total of 65 isolates from 33 CF patients were analyzed
through antibiotic susceptibility testing. The minimal period
between isolation of the strains was four weeks. Etest strips
(Liofilchem, Roseto degli Abruzzi, Italy) containing ceftazi-
dime, colistin, fosfomycin, levofloxacin, moxifloxacin, ticarcillin–
clavulanate, trimethoprim–sulfamethoxazole, and tigecycline were
used. MIC tests were performed according to Clinical and
Laboratory Standards Institute (CLSI) guidelines (M07-A8)
Fig. 2. Frequency of microorganisms isolated from 623 sputum samples from
165 CF patients by conventional media.
Table 1
Demographic characteristics of 165 CF patients according to medical interest of
species isolation.
Patient features Aspergillus spp. Pseudomonas spp. S. maltophilia
Mean age±SD
(range)
24.1±6.5 (1–51) 27.4±8.2 (5–79) 22.2±8.8 (1–51)
Female (%) 36.6 39.5 57.5
Total (n) 71 91 33
SD = standard deviation.
Fig. 1. Algorithm of S. maltophilia identification.
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tested for quality assurance purposes. A suspension of each
isolate was adjusted to the density of 0.5 McFarland standard
and was plated on Mueller–Hinton agar in three directions to
ensure uniform growth. After the agar surface was completely
dry, Etest strips were applied. The plates were incubated at
35 °C for 24 h. The MIC was interpreted (according to the
manufacturer's guidelines) as the zone of growth inhibition
that intersected the Etest strip. CLSI has established general
interpretative criteria for susceptibility breakpoints for
S. maltophilia, except for colistin and moxifloxacin. Thus,
the breakpoints established for P. aeruginosa for these antimi-
crobial agents were applied [14,15]. Seven samples could not be
saved for susceptibility testing.
3. Results
3.1. Isolation of microorganisms by conventional media and
selective media
A total of 623 sputum samples from 165 CF patients were
collected during the 25 months of this study period. The most
frequently identified microorganisms were yeasts (52.4%),
followed by Pseudomonas spp. (52.0%), Staphylococcus
aureus (48.3%), and Aspergillus spp. (31.7%). The frequency
of bacterial and fungal isolates in relation to all samples
analyzed is presented in Fig. 2.
In total, S. maltophiliawas isolated in 72 sputum samples from
33 patients aged 1 to 51 years. Conventional media support the
growth of S. maltophilia in 7.1% of the samples. However, thedetection rate increased to 11.6% when selective media were
used. Thus, the selective media supported the growth of 64%
more S. maltophilia isolates than the conventional media.
There was not a case, in which the conventional media
detected a S. maltophilia isolate and selective medium did
not. In general, S. maltophilia was isolated with other
accompanying facultative pathogenic species, such as
Aspergillus fumigatus (30.6%), Candida albicans (46.3%),
and P. aeruginosa (39.6%). Patient features related to the
detection of Aspergillus spp., Pseudomonas spp., and
S. maltophilia are presented in Table 1. In contrast to
Aspergillus spp. and Pseudomonas spp., S. maltophilia was
detected more frequently in female patients than in male
patients.3.2. Antimicrobial susceptibility testing
Table 2 summarizes the MICs at which 50% (MIC50) and
90% (MIC90) of S. maltophilia isolates were inhibited, as well
as the percentage of susceptible and resistant isolates.
Among all agents tested, tigecycline andtrimethoprim–
sulfamethoxazole exhibited the highest in vitro activity against
S. maltophilia (98%–100% susceptibility). Good activity
(89%–92% susceptibility) was also observed for the quinolones
(levofloxacin, moxifloxacin), and fosfomycin. In contrast,
colistin, ceftazidime, and ticarcillin–clavulanate acid exhibited
limited activity (44%–64% susceptibility).
Table 2
In vitro activity of eight antimicrobial agents tested against S. maltophilia by Etest.
Antimicrobial agent MIC (μg/mL) % (n=65) of strains
Range (μg/mL) 50% of strains 90% of strains Susceptible Intermediate Resistant
Ceftazidimine 0.016–256 3 32 63.0 7.6 29.4
Colistin 0.016–256 3 12 40.0 29.2 30.8
Fosfomycin 0.016–256 6 12 92.3 – 7.7
Levofloxacin 0.002–32 0.625 2 92.3 – 7.7
Moxifloxacin 0.002–32 0.25 1 89.5 7.5 3.0
Ticarcillin–clavulanate acid 0.016–256 4 32 64.1 16.4 19.5
Tigecycline 0.016–256 0.094 0.218 98.4 – 1.6
Trimethoprim–sulfamethoxazole 0.002–32 0.38 1 100 – –
MIC = minimum inhibitory concentration. MICs at which 50 (MIC50) and 90% (MIC90) of S. maltophilia isolates were inhibited.
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Currently, reports from several centers worldwide have
documented the increasing isolation of S. maltophilia in CF
patients; however, clinical management depends on accurate
identification and susceptibility testing of this pathogen in the
microbiological laboratory. A standardized and low-cost
medium designed to selectively grow medically important
pathogens, such as P. aeruginosa or B. cepacia, has been
recommended by various authors [8,9]. However, no selective
medium for improved detection of S. maltophilia has yet been
recommended by international guidelines, nor is such a medium
yet commercially available.
The first report (1989) of a selective medium (XMSM) for
the isolation of S. maltophilia from soil and rhizosphere
environments was published by Juhnke and Jardin [16]. The
XMSM medium is a tryptone-based medium supplemented
with six antimicrobial agents (bacitracin, cephalexin, neomycin,
novobiocin, penicillin G, tobramycin), two antifungal agents
(cycloheximide and nystatin), maltose and bromothymol blue.
Later, Kerr et al. [12] developed the VIA agar, which contained
vancomycin (5 mg/L), imipenem (32 mg/L), and amphotericin
B (2.5 mg/L) as selective agents. This medium also included a
mannitol/bromothymol indicator system (S. maltophilia does
not produce acid from mannitol). These authors compared the
selective properties of VIA and XMSM agar by using fecal
samples from 32 children with hematological malignancy. The
results demonstrated that VIA agar was clearly superior to
XMSM in selectivity because it did not allow the growth of
microorganisms other than S. maltophilia.
In 2000, Denton et al. [17] demonstrated the improved
isolation of S. maltophilia in 814 sputum samples from CF
patients by using VIA agar with a minor modification
(increasing the amphotericin B concentration from 2.5 to
4 mg/L). These authors noted that VIA agar supported the
growth of 54.8% more S. maltophilia isolates than did
bacitracin-chocolate agar (BC medium). A group from Australia
[18] proposed another modification of VIA agar (mVIA) for
isolating S. maltophilia from environmental and clinical
samples: incorporating meropenem (16 mg/L) instead of
imipenem. This modified medium demonstrated 62% specific-
ity for S. maltophilia, and all other bacteria present could beeasily distinguished. The authors also stated that substituting
meropenem for imipenem may have reduced the sensitivity of
mVIA agar.
In fact, our slightly modified SMA has no obvious advantages
over the VIA agar. However, in this study the improved detection
of S.maltophilia by the SMAconfirmed the findings fromDenton
et al. [17] and due to the increasing prevalence of this emerging
pathogen in the last decade, we suggest the use of a selective agar
for isolation of S. maltophilia in sputum samples from CF
patients. Guidelines for the laboratory diagnosis of respiratory
infections in CF patients have been established. However, the use
of a selective medium for the isolation of S. maltophilia has not
been recommended yet by international societies [19,20]. For the
detection of S. maltophilia and other atypical respiratory
pathogens, British and German guidelines state that such
microorganisms will grow on blood agar and McConkey agar.
Both media, in this present study, in addition to others helped to
detect S. maltophilia in 7.1% from all analyzed samples; whereas
SMAwas able to support the growth of 64% more S. maltophilia
isolates than the conventional media. In addition, SMA is very
easy to formulate, and the processing of sputum is quite fast and
normally does not require special pretreatment. However, because
of the gradual reduction of imipenem activity over time, this
medium can be used for only 3 weeks.
The most frequently detected microorganisms in this study
were S. aureus, Pseudomonas spp., and Aspergillus spp. These
results were similar to those of previously published reports [1,2].
In our single-center cohort, the mean age of patients with S.
maltophilia infection was 22.2 years, and the organism was more
likely to be found in female patients. These observations are in
line with the results of a study by Goss et al. [21], which analyzed
data collected from 1991 to 1997 at centers accredited by the U.S.
Cystic Fibrosis Foundation. S. maltophilia was detected at least
once in each of 1673 patients with a mean age of 18.9 years; the
organism was more likely to be detected in female patients.
Regarding antimicrobial susceptibility, only a few studies have
performed susceptibility testing for S. maltophilia on samples
from CF patients. The results of the present study demonstrated
that tigecycline and trimethoprim–sulfamethoxazole exhibited
excellent activity against S. maltophilia. Fosfomycin, a phos-
phonic acid antibiotic with few reports of human toxicity [22],
also exhibited low MICs against S. maltophilia. On the other
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exhibited low activity against this pathogen.
Cantón et al. [23] evaluated 41 antimicrobial agents against 76
S. maltophilia isolates from CF patients admitted to the Ramón y
Cajal Hospital CF Unit, Madrid, Spain. The resistance rates they
reported for ceftazidime (70.0%), ticarcillin–clavulanate (47.0%),
and trimethoprim–sulfamethoxazole (25.4%) were higher than
those in the present study, whereas the resistance rates for
moxifloxacin (6.3%) and levofloxacin were lower.
In addition, Gabriel et al. [11] studied the antimicrobial
susceptibility of 673 S. maltophilia isolates from patients
who attended the CF Referral Center at Columbia Univer-
sity, New York City, USA. These authors performed broth
microdilution assays and observed higher resistance rates for
trimethoprim–sulfamethoxazole (84%) than those found in
our study, but the ticarcillin–clavulanate MICs were
consistent with our results.
Recently, a Turkish research group [24] examined
genotype and antibiotic susceptibility patterns of a small
number of S. maltophilia isolates (n=11). According to the
results, trimethoprim–sulfamethoxazole was the most active
antibiotic (all isolates were susceptible), whereas levoflox-
acin demonstrated good activity (82% of isolates were
susceptible). In Northern Ireland, Mcknight et al. [25]
verified the in vitro antibiotic susceptibility (Etest) of
levofloxacin against 10 S. maltophilia isolates obtained
from adult and pediatric CF patients. The results indicated
again that levofloxacin exhibited excellent inhibitory activity
against this microorganism. More recently, King et al. [26]
evaluated the in vitro activity of five antimicrobial agents
against gram-negative clinical isolates, including S. mal-
tophilia (n=51). The CF patients attended one of three
American CF Centres or one French hospital. The authors
concluded that levofloxacin was the most potent antibiotic
against all CF isolates. These results are in nearly
complete agreement with our finding that 92% of S.
maltophilia isolates from CF patients were susceptible to
levofloxacin.
Colistin demonstrated limited activity against S. mal-
tophilia isolates from CF patients. However, it is important
to mention that colistin is normally used as inhaled agent to
treat CF patients. Since interpretative criteria for in vitro
susceptibility testing are designed for systemic use, the data
presented in this study requires further investigations
regarding potential inhibitory effects of inhaled agents.
Until now, CLSI guidelines have not yet established specific
breakpoints as interpretive criteria for moxifloxacin and
colistin against S. maltophilia.
To the best of our knowledge, ours is the first study to
evaluate the inhibitory effects of colistin, fosfomycin and
tigecycline against clinical CF S. maltophilia isolates. In
fact, fosfomycin, levofloxacin, moxifloxacin, trimethoprim–
sulfamethoxazole, and tigecycline may be effective in
treating infections caused by S. maltophilia in CF patients.
For this reason, it is important to conduct further clinical
studies to evaluate the in vivo efficacy of these compounds
and their impact on CF patients.5. Conclusion
In summary, our results clearly demonstrate the importance
of using a selective medium for culturing S. maltophilia in
sputum samples from CF patients. Analyses of the antimicrobial
susceptibilities of eight drugs revealed that trimethoprim–
sulfamethoxazole and tigecycline demonstrated the highest in
vitro activity against S. maltophilia, whereas colistin was the
least effective.
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